Jean L. Rouleau

发表

Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.

Adrian F Hernandez, Anita Deswal, Christopher M O'Connor, 2013, JAMA.

β-blocker Therapy is Not Associated with Reductions in Angina or Cardiovascular Events After Coronary Artery Bypass Graft Surgery: Insights from the IMAGINE Trial

J. Rouleau, W. V. van Gilst, J. Warnica, 2015, Cardiovascular Drugs and Therapy.

Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.

J. Rouleau, J. Arnold, M. Packer, 1994, Journal of the American College of Cardiology.

Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

E. Braunwald, K. A. Hill, Daniel J. Rader, 2004, The New England journal of medicine.

Incidence of Sudden Cardiac Death in National Collegiate Athletic Association Athletes

R. Califf, S. Zelenkofske, J. Drezner, 2012 .

The cardiac endothelium: functional morphology, development, and physiology.

J. Rouleau, G. D. De Keulenaer, D. Brutsaert, 1996, Progress in cardiovascular diseases.

Rhythm control versus rate control for atrial fibrillation and heart failure.

J. Le Heuzey, A. Ducharme, M. Talajic, 2008, The New England journal of medicine.

Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction

P. Jhund, M. Vaduganathan, M. Packer, 2023, European journal of heart failure.

Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF

Akshay S. Desai, S. Solomon, M. Pfeffer, 2021, Journal of the American Heart Association.

Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.

M. Pfeffer, S. Yusuf, J. McMurray, 2000, American heart journal.

Clinical Trial: Methods and Design Cardiorenal Rescue Study in Acute Decompensated Heart Failure: Rationale and Design of CARRESS-HF, for the Heart Failure Clinical Research Network

E. Braunwald, G. Felker, D. Mann, 2012 .

Knowledge about self‐efficacy and outcomes in patients with heart failure and reduced ejection fraction

P. Jhund, M. Vaduganathan, M. Packer, 2023, European journal of heart failure.

Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

M. Pfeffer, B. Gersh, M. Rice, 2005 .

High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT.

S. de Denus, Jiankang Liu, B. Claggett, 2024, International journal of cardiology.

Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysis.

S. Solomon, M. Pfeffer, J. Rouleau, 2001, American heart journal.

The importance of microalbuminuria as a cardiovascular risk indicator: A review.

J. Rouleau, P. D. de Jong, W. V. van Gilst, 2002, The Canadian journal of cardiology.

Effects of sacubitril/valsartan according to polypharmacy status in PARAGON‐HF

P. Jhund, M. Vaduganathan, Li Shen, 2024, European journal of heart failure.

Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials.

P. Jhund, M. Vaduganathan, B. Claggett, 2024, JAMA cardiology.

Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

P. Jhund, M. Vaduganathan, F. Zannad, 2023, European journal of heart failure.